gsk1322322 and Respiratory-Tract-Infections

gsk1322322 has been researched along with Respiratory-Tract-Infections* in 2 studies

Trials

1 trial(s) available for gsk1322322 and Respiratory-Tract-Infections

ArticleYear
Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1

    GSK1322322 is a potent peptide deformylase inhibitor with in vitro and in vivo activity against multidrug-resistant skin and respiratory pathogens. This report provides plasma and intrapulmonary pharmacokinetics, safety, and tolerability of GSK1322322 after repeat (twice daily intravenous dosing for 4 days) dosing at 1,500 mg. Plasma samples were collected over the last 12-hour dosing interval of repeat dosing following the day 4 morning dose (the last dose). Bronchoalveolar lavage samples were collected once in each subject, either before or at 2 or 6 h after the last intravenous dose. Plasma area under the concentration-time curve (AUC0-τ) was 66.7 μg · h/ml, and maximum concentration of drug in serum (Cmax) was 25.4 μg/ml following repeat doses of intravenous GSK1322322. The time course of epithelial lining fluid (ELF) and alveolar macrophages (AM) mirrored the plasma concentration-time profile. The AUC0-τ for ELF and AM were 78.9 μg · h/ml and 169 μg · h/ml, respectively. The AUC0-τ ratios of ELF and AM to total plasma were 1.2 and 2.5, respectively. These ratios increased to 3.5 and 7.4, respectively, when unbound plasma was considered. These results are supportive of GSK1322322 as a potential antimicrobial agent for the treatment of lower respiratory tract bacterial infections caused by susceptible pathogens. (This study has been registered at ClinicalTrials.gov under registration number NCT01610388.).

    Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Bronchoalveolar Lavage; Female; Humans; Hydroxamic Acids; Macrophages, Alveolar; Male; Middle Aged; Respiratory Tract Infections; Young Adult

2014

Other Studies

1 other study(ies) available for gsk1322322 and Respiratory-Tract-Infections

ArticleYear
Discovery of piperazic acid peptide deformylase inhibitors with in vivo activity for respiratory tract and skin infections.
    Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16

    The discovery of a novel series of peptide deformylase inhibitors incorporating a piperazic acid amino acid found in nature is described. These compounds demonstrated potent in vitro enzymatic potency and antimicrobial activity. Crystal structure analysis revealed the piperazic acid optimized a key contact with the PDF protein that accounted for the increased enzymatic potency of these compounds. We describe lead optimization of the P3' region of the series that resulted in a compound with good potency against three target organisms. One molecule showed in vivo efficacy in a rat respiratory infection model but ultimately did not meet candidate progression criteria.

    Topics: Amidohydrolases; Anti-Bacterial Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Haemophilus influenzae; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridazines; Respiratory Tract Infections; Skin Diseases, Infectious; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship

2019